Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

Inclusion Criteria:

Adult ≥18 years old
Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV)
Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK)
Cohort A: Received first line treatment with pembrolizumab monotherapy
Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy
Cohort C: Received first line treatment with chemotherapy doublet

Exclusion Criteria:

Prior anti-cancer therapy for actual stage IV NSCLC
Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging)
Patients participating in other clinical trials that modify the standard of care